Q1 2025 Management View CEO Brian Lian highlighted the company's progress in advancing its VK2735 obesity program, with Phase ...

Welcome to the Viking Therapeutics First Quarter 2025 Financial ... Joining me today is Brian Lian, Viking's President and CEO; and Greg Zante, Viking's CFO. Before we begin, I'd like to caution ...

Viking Therapeutics releases its first-quarter results after Wednesday's closing bell. Here's a look at the details from the ...

Viking Therapeutics Inc (NASDAQ ... comparing the vial and syringe to the auto-injector in the interim. - Brian Lian, CEO Q: What specific level of weight loss are you looking to achieve in ...

Viking continued to build on the strong momentum achieved in 2024,” stated Brian Lian, Ph.D., chief executive officer of Viking. “Throughout the first quarter we continued to ramp up activities in ...

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian ...

Highlights from the Quarter Ended March 31, 2025, and Other Recent Events: "In the first quarter of 2025 Viking continued to build on the strong momentum achieved in 2024," stated Brian Lian ...

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian ...

CEO Brian Lian highlighted the company's progress ... treatments and potential delays in Phase 3 trial timelines. Viking Therapeutics is poised for significant developments in 2025, with Phase ...

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian ...

Viking Therapeutics Inc (VKTX) reports significant progress in clinical trials and maintains a strong cash position despite ...